23 November 2017

NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.

Please note that this agenda is subject to change prior to the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Appraisal of sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C [ID1055]
    • 4.1. Declarations of interest – Part 1 only (open session)
    • 4.2. Introduction by the Vice Chair, Dr Lindsay Smith – Part 1 only (open session)
    • 4.3. Presentation by the lead team, Dr Aomesh Bhatt, Dr David Meads and Dr Malcolm Oswald – Part 1 AND part 2 (open and closed session)
    • 4.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  5. Appraisal of dinutuximab beta EUSA for treating high-risk neuroblastoma [ID910]
    • 5.1. Declarations of interest – Part 1 only (open session)
    • 5.2. Introduction by the Chair, Professor Gary McVeigh – Part 1 only (open session)
    • 5.3. Presentation by the lead team, Dr Peter Hall, Dr Malcolm Oswald and Mr William Turner – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy [ID1327]
    • 6.1. Declarations of interest – Part 1 only (open session)
    • 6.2. Introduction by the Chair, Professor Gary McVeigh  Part 1 only (open session)
    • 6.3. Presentation by the Chair, Professor Gary McVeigh Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995]
    • 7.1. Declarations of interest – Part 1 only (open session)
    • 7.2. Introduction by the Chair, Professor Gary McVeigh Part 1 only (open session)
    • 7.3. Presentation by the Chair, Professor Gary McVeigh Part 1 AND part 2 (open and closed session)
    • 7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Tuesday 9 January 2018 at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Thursday 9 November 2017Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Zandra Taylor.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 26 October 2017 to 09 November 2017
Registration is closed.